Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Many osteoporosis patients have low 25-hydroxyvitamin D (25OHD) and do not take recommended vitamin D amounts.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

This 15-week, randomized, double-blind, multi-center, active-controlled study was conducted during a season when 25OHD levels are declining, and patients were required to avoid sunlight and vitamin D supplements for the duration of the study.

Men (n = 35) and postmenopausal women (n = 682) with osteoporosis and 25OHD >or= 9 ng/mL were randomized to ALN + D (n = 360) or ALN (n = 357).

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

PubMed files the paper under topics including Alendronate, Bone and Bones, Cholecalciferol, Drug Combinations, Osteoporosis, Osteoporosis, Postmenopausal and Parathyroid Hormone.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Current medical research and opinion), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.